Modulation of estrogen related receptor alpha activity by the kinesin KIF17 by Seneviratne, A. M. Pramodh Bandara et al.
Oncotarget50359www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 31), pp: 50359-50375
Modulation of estrogen related receptor alpha activity by the 
kinesin KIF17
AM Pramodh Bandara Seneviratne1,2,4, Zeynep Turan2,7, Aurelie Hermant3, Patrick 
Lecine3,6, William O. Smith2, Jean-Paul Borg3, Fanny Jaulin2,5 and Geri Kreitzer1,2,4
1 Department of Molecular, Cellular & Biomedical Sciences, The City University of New York School of Medicine, New York, 
NY, USA
2 Department of Cell and Developmental Biology, Weill Medical College, Cornell University, New York, NY, USA
3 Centre de Recherche en Cancérologie de Marseille, Aix Marseille Univ UM105, Institut Paoli-Calmettes, UMR7258 CNRS, 
U1068 INSERM, Cell Polarity, Cell Signalling and Cancer, Equipe labellisée Ligue Contre le Cancer, Marseille, France
4 The City University of New York School of Medicine, New York, NY, USA
5 Gustave Roussy Institute, Villejuif, France
6 BIOASTER, Tony Garnier, Lyon, France
7 California Institute of Technology, Pasadena, CA, USA
Correspondence to: Geri Kreitzer, email: gkreitzer@med.cuny.edu
Keywords: kinesin, estrogen related receptor alpha, transcription, breast cancer, epithelial
Received: August 06, 2015 Accepted: May 12, 2017 Published: May 23, 2017
Copyright: Seneviratne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Estrogen-related receptor alpha (ERR1) is an orphan nuclear receptor that can 
bind transcriptional co-activators constitutively. ERR1 expression correlates with 
poor patient outcomes in breast cancer, heightening interest in this nuclear receptor 
as a therapeutic target. Because ERR1 has no known regulatory ligand, a major 
challenge in targeting its activity is to find cellular or synthetic modulators of its 
function. We identified an interaction between ERR1 and KIF17, a kinesin-2 family 
microtubule motor, in a yeast-2-hybrid screen. We confirmed the interaction using 
in vitro biochemical assays and determined that binding is mediated by the ERR1 
ligand-binding/AF2 domain and the KIF17 C-terminal tail. Expression of KIF17 tail 
domain in either ER-negative or ER-positive breast cancer epithelial cells attenuated 
nuclear accumulation of newly synthesized ERR1 and inhibited ERR1 transcriptional 
activity. Conversely, ERR1 transcriptional activity was elevated significantly in KIF17 
knock-out cells. Sequence analysis of the KIF17 tail domain revealed it contains 
a nuclear receptor box with a conserved LXXLL motif found in transcriptional co-
activators. Expression of a 12 amino-acid peptide containing this motif was sufficient 
to inhibit ERR1 transcriptional activity and cell invasion, while deletion of this region 
from the KIF17 tail resulted in increased ERR1 activity. Together, these data suggest 
KIF17 modifies ERR1 function by two possible, non-exclusive mechanisms: (i) by 
regulating nuclear-cytoplasmic distribution or (ii) by competing with transcriptional 
co-activators for binding to ERR1. Thus targeting the ERR1-KIF17 interaction has 
potential as a novel strategy for treating breast cancer.
INTRODUCTION
Estrogen related receptor alpha (ERR1) is an orphan 
nuclear receptor that regulates genes involved in adaptive 
energy and lipid metabolism, mitochondrial biogenesis, 
osteogenesis, thermogenesis and ion homeostasis [1, 
2]. ERR1 regulates transcription of its gene targets by 
binding to specific ERR response elements (ERREs) 
[3-5]. In addition, ERR1 can activate transcription 
of estrogen receptor alpha (ER) target genes through 
multiple, imperfect estrogen receptor response element 
(ERE) half-sites, although this occurs primarily in cells 
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lacking ER [4, 6-10]. ERR1 has a ligand binding pocket, 
but no natural ligand has been identified to date and ERR1 
can bind its coactivators constitutively [9, 11]. However, 
ERR1 function can be modified in response to signaling 
through EGF, ErbB2 and IGF-1R, which affect its binding 
to co-activators and repressors, its transcriptional activity, 
and its targeting for degradation [12-14]. ERR1 activity 
may also be regulated by competition with ER for binding 
to transcriptional co-factors, as it is known to modulate 
responses to estrogen by competing with ER for binding 
to EREs on target DNA and to regulatory co-activators or 
co-repressors [15-17].
ERR1 expression correlates with poor prognoses in 
breast cancer, particularly in patients with ER-negative, 
ER-negative/ErbB2-positive, and triple-negative tumors. 
As such, it has gained attention as a potent factor 
and possible therapeutic target in treating aggressive 
disease [18]. Small molecule, selective, inverse-agonists 
occupy the ERR1 ligand binding domain and induce a 
conformational change in ERR1 that inhibits binding of 
ERR1 co-activators, leading ultimately to degradation 
of ERR1 by the proteasome [19-22]. Importantly, ERR1 
inverse agonists are effective in inhibiting orthotopic 
breast tumor growth in murine models [23, 24]. To date 
however, there is no evidence that these agents are in 
clinical trial  - perhaps because they would be predicted 
to induce systemic toxicity in view of ERR1’s regulation 
of genes in multiple essential pathways. Consequently, a 
key step in development of clinically viable anti-ERR1 
therapies is to identify cellular or synthetic modulators 
that affect only subsets of ERR1-regulated genes that are 
altered in the disease state.
We identified ERR1 as a binding partner of the 
kinesin-2 family motor protein KIF17. Kinesins are 
microtubule (MT) stimulated ATPases that transport a 
variety of soluble and membrane-bound cargoes within the 
cell [25, 26]. In humans, the kinesin family is comprised of 
over 40 related proteins that share structural and functional 
motifs. Kinesin motor domains are highly conserved and 
bind MTs and ATP. Kinesin tail domains interact with 
numerous cellular cargoes but are highly divergent, 
contributing in large part to the uniqueness between family 
members. Kinesins are known to participate in regulation 
of transcriptional signaling [27-30], but their potential to 
modulate nuclear receptor activity directly in breast cancer 
has not been investigated. The studies described here show 
that in ER-positive and ER-negative breast cancer cells, 
ERR1 localization and activity can be regulated by KIF17. 
Notably, a 12 amino acid peptide within the KIF17 tail 
is necessary and sufficient to inhibit ERR1 function. This 
peptide contains a conserved LXXLL nuclear receptor box 
motif (NR box) found in nuclear receptor co-activators 
[31-33]. The LXXLL co-activator motif is sufficient for 
nuclear receptor (NR) binding. However, flanking amino 
acids influence which of the many co-activators bind NRs 
(e.g. in response to signaling); this affects expression 
of distinct gene targets and likely downstream cellular 
pathways [31-33]. The NR box in KIF17 shares features 
with a subset of NR co-activators [31], suggesting that a 
KIF17 peptide containing this NR box could be exploited 
to inhibit a subset of ERR1-responsive genes. This could 
lead to development of new therapeutic strategies targeting 
ERR1 in breast and potentially other steroidogenic and 
non-steroidogenic cancers. 
RESULTS
ERR1 interacts with KIF17
We identified ERR1 as a binding partner of the 
homodimeric kinesin-2 family motor KIF17 in a yeast-
2-hybrid screen of normal epithelial cells using the 
KIF17 C-terminal tail domain as bait (KIF17-T, Figure 
1A). Yeast-2-hybrid clones encoding the ligand-binding 
and activator function-2 domains (LB/AF2) of ERR1 
were the most abundant of twenty-three distinct hits in 
iterative screening. We validated the interaction by co-
immunoprecipitation using HEK-293 cells expressing 
the yeast-2-hybrid bait and prey clones. We transfected 
cells with myc-tagged KIF17-T and either GFP-tagged 
ERR1-LB/AF2 or control GFP-empty vector (GFP-EV). 
One day later we performed co-immunoprecipitation 
analysis using anti-myc antibodies. In these experiments, 
GFP-ERR1-LB/AF2, but not GFP-EV, co-precipitated 
with myc-KIF17-T (Figure 1B). We next performed 
endogenous co-immunoprecipitation experiments in 
ER-positive MCF-7 breast cancer epithelial cells. Cell 
lysates were incubated with non-specific control IgG or 
with anti-ERR1 IgG and applied to protein-G sepharose 
to isolate immune complexes. After separation by SDS 
PAGE, immunoblot analysis confirmed that endogenous 
KIF17 co-immunoprecipitated with ERR1 IgG, but not 
non-specific IgG (Figure 1C). Co-immunoprecipitation of 
endogenous ERR1 and KIF17 was also detected in ER-
negative MDA-MB-231 cells (not shown). This interaction 
may be transient, as significant KIF17 was found in non-
binding and wash fractions in these assays. Alternatively, 
the relatively high level of unbound KIF17 may reflect 
limiting amounts of ERR1 relative to KIF17. 
To determine if the interaction between ERR1 and 
KIF17 is selective, we next tested if KIF17-T interacts 
with other ERR family members, and if ERR1 interacts 
with other kinesin family members. ERR1 is one of three 
ERR family members: ERR1, ERR2 (ERR beta) and 
ERR3 (ERR gamma). ERR1 is expressed ubiquitously 
while ERR3 has a more restricted tissue distribution [34, 
35]. ERR2 expression is limited primarily to embryonic 
tissues and we do not consider it further in these studies. 
We co-transfected HEK-293 cells with cDNAs encoding 
myc-KIF17-T and either GFP-ERR1 or GFP-ERR3. 
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One day later we performed co-immunoprecipitation 
analysis using anti-myc antibodies. Although ERR1 and 
ERR3 share significant sequence identity in their LB/AF2 
domains [36], GFP-ERR3 does not co-immunoprecipitate 
with myc-KIF17-T (Figure 1D). Moreover, in parallel 
experiments, we found that GFP-ERR1 does not interact 
with the tail domain of the kinesin-3 family motor KIF1A 
(myc-KIF1A-T) (Figure 1E). Consistent with this finding, 
GFP-ERR1 from cell lysates was pulled down by purified, 
recombinant GST-tagged KIF17-T and full-length KIF17 
immobilized on glutathione-sepharose beads, but not by 
GST-KIF1A-T (not shown). Together, these data show a 
selective interaction between KIF17 and ERR1.
Expression of KIF17-Tail inhibits ERR1 
transcriptional activity in breast cancer cells
To determine if the interaction of KIF17 with 
ERR1 has functional significance, we tested the effects of 
expressing KIF17-T on ERR1 transcriptional activity in 
ER-positive and ER-negative cells. MCF-7 (Figure 2A), 
MDA-MB-231 (Figure 2B) or MCF-10a (not shown) 
cells were co-transfected with the ERR1 responsive 
element fused to luciferase (ERRE-Luc; [37]) and 
mCherry-tagged KIF17-T (mCh-KIF17-T) or control, 
empty vector (mCh-EV). Luminescence was measured 
Figure 1: KIF17 interacts selectively with ERR1. A. Schematic diagrams of KIF17 and ERR1 and their interacting domains 
identified in the yeast-2-hybrid screen. B. Co-immunoprecipitation of GFP-ERR1 LB/AF2 domain with myc-KIF17-tail in HEK293T 
cells. Upper left lane shows the ~25kDa marker region where GFP migrates; upper right shows marker at 50kDa for GFP-ERR1-LBD/
AF2 migration. C. Co-immunoprecipitation of endogenous KIF17 and ERR1 from MCF7 cells. D. Co-immunoprecipitation analysis of 
myc-KIF17-T and full-length GFP-ERR1 or GFP-ERR3 expressed in HEK-293T cells. Note that immunoprecipitated GFP-ERR1 routinely 
migrates more slowly than the majority of total GFP-ERR1 detected in input lanes. E. Co-immunoprecipitation analysis of full-length GFP-
ERR1 and myc-KIF17-T or myc-KIF1A-T expressed in HEK-293T cells. Inputs in D and E represents 10% of total lysate from HEK293T 
cells expressing the indicated constructs. Asterisks in E show myc-tagged kinesin tails. Additional bands in the IP are IgG light chains. 
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24 hours after transfection as a readout of transcriptional 
activity. In control cells (mCh-EV, normalized to 100%), 
luminescence signal was routinely robust. In cells 
expressing mCh-KIF17-T, we measured a significant 
reduction in luminescence when normalized to controls. 
ERR1 and ER alpha share ~30% identity in their 
LBD/AF2 domains [38], and ERR1 can activate a 
subset of ER transcriptional targets using ER responsive 
elements (ERE) [4, 6-10]. Considering this, we also tested 
if KIF17-T interacts with and impacts ER transcriptional 
activity, or if it is selective for ERR1. Co-expression of 
KIF17-T with an ER reporter, ERE-Luc [39], had no effect 
on luminescence in either ER-positive (Figure 2A) or ER-
negative (Figure 2B) cell lines. In addition, ER did not co-
immunoprecipitate with KIF17-T (not shown). These data 
further show that the KIF17 tail acts on ERR1 selectively 
and irrespective of ER status. 
The above data demonstrate effects of an 
overexpressed KIF17 fragment on ERR1. To determine if 
KIF17 plays a physiological role in regulating ERR1, we 
analyzed ERRE-Luc reporter activity in genome-edited, 
KIF17 knock-out T84 human colon epithelial cells (KIF17-
/-, Figure 2C). Wild-type T84 cells (KIF17+/+) and genome 
edited cells were co-transfected with ERRE-Luc and 
Figure 2: KIF17-Tail inhibits transcriptional activity of ERR1 on the ERRE, but not the ERE, in both ER-positive 
and ER-negative breast cancer cells. Luciferase reporter assays showing transcriptional activity of endogenous ERR1 in A. MCF-7 
and B. MDA-MB-231. C. Western blot for KIF17 in parental T84 cells (KIF17+/+) and T84 cells in which KIF17 was deleted by genome 
editing (KIF17-/-). D. Luciferase reporter assay in T84 wild type and KIF17 knock-out cells expressing GFP-KIF17-T or control GFP-EV 
and ERRE-Luc or ERE-Luc. Graphs show luminescence values normalized to GFP-EV. Error bars = SEM, ***p < 0.05. In panel D, GFP-
EV is also normalized to parental, KIF17+/+ cells. Error bars = SEM, ‡p < 0.05. Data is pooled from ≥ 3 experiments performed in triplicate. 
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mCh-EV control or mCh-KIF17-T, and luminescence was 
measured 24 hours later. In KIF17-/- cells co-expressing 
mCh-EV, ERRE-Luc luminescence was elevated 
significantly as compared with KIF17+/+ cells (Figure 2D). 
Importantly, this increase was reversed when cells were 
also co-transfected with mCh-KIF17-T, demonstrating that 
the KIF17 tail domain can inhibit ERR1 activity in cells 
lacking endogenous KIF17. Together, these data suggest 
KIF17 acts as a repressor of ERR1 transcriptional activity. 
Expression of KIF17-Tail inhibits nuclear 
translocation of ERR1 in breast cancer cells
Immunofluorescence analysis of endogenous ERR1 
and KIF17 in ER-positive and ER-negative cells showed 
that ERR1 and KIF17 localized in the cytoplasm and 
nucleus (Figure 3A, upper panels). KIF17 also localized 
on MTs, as expected for a MT-associated motor and as 
described previously [40], and nuclear KIF17 was not 
unexpected as it contains a nuclear localization signal 
(NLS) in its C-terminal tail (see Figure 4A and [41]). 
Although cytoplasmic KIF17 and ERR1 puncta were 
numerous, we only measured a significant colocalization 
between the two proteins when we analyzed their 
distributions specifically along MTs. Line-scan analysis 
of ERR1 and KIF17 along MTs (Figure 3A, lower panels, 
graph and table) revealed that 37% of ERR1 puncta 
colocalized with KIF17, as compared with 18% measured 
after shifting the KIF17 image by 5 pixels to detect 
random co-distribution. 
Kinesin-tail domains often have dominant-negative 
effects on protein translocation when overexpressed in 
cells, as they bind cargo but do not move on MTs [25, 
42]. Because a portion of cytoplasmic ERR1 colocalized 
with KIF17 on MTs, we tested if expression of KIF17-T 
affected translocation of ERR1 from the cytoplasm to 
the nucleus. We expressed GFP-ERR1 in cells acutely 
by cDNA injection and monitored newly synthesized 
protein by time-lapse fluorescence microscopy (Figure 
3B). ER-positive and ER-negative cells were injected 
with GFP-ERR1 and mCh-EV or mCh-KIF17-T cDNAs 
and incubated for 90 minutes to allow for protein 
expression. Cells were then transferred to a temperature-
controlled chamber on the microscope and imaged live at 
10min intervals for 180min. After image acquisition, we 
quantified GFP-ERR1 fluorescence in individual cells and 
cell nuclei and determined the ratio of nuclear:total GFP 
(N/T) per cell over time (Figure 3B and Table in 3C). At 
the start of recordings, most GFP-ERR1 localized to the 
cytoplasm with only ~15-25% in the nucleus in MCF-
7 and MCF-10a cells (Figure 3C). In control cells co-
expressing mCh-EV, ~40-50% of GFP-ERR1 localized to 
the nucleus 3h later. By contrast, in cells co-expressing 
mCh-KIF17-T, only ~30% of GFP-ERR1 localized in 
the nuclear compartment. Thus relative to control cells 
expressing GFP-EV, KIF17-T reduced nuclear GFP-
ERR1 by accumulation 25-35%. Because the KIF17-
tail encodes an NLS, a large fraction of mCh-KIF17-T 
also accumulated in nuclei (Figure 3C, insets); this 
likely impinges on the ability of expressed KIF17-T to 
maximally inhibit ERR1 nuclear translocation in these 
assays. Despite this limitation, our results suggest that one 
way the KIF17 tail affects ERR1 transcriptional function 
is by inhibiting its accumulation in the nucleus. 
If KIF17 acts as an active transporter of ERR1 we 
would expect ERR1 nuclear accumulation to be dependent 
on an intact MT array. To test this, we treated cells with 
the MT depolymerizing agent nocodazole (NZ; 33µM) 
immediately following cDNA injection. NZ treatment 
accelerated the accumulation of nuclear GFP-ERR1 
in all cells at early time points of the recording, but did 
not alter the final proportion of nuclear:total GFP-ERR1 
in cells expressing either mCh-EV or mCh-KIF17-T 
(Figure 3C, Table). This suggests KIF17-T affects nuclear 
translocation of ERR1 by sequestering it on MTs and 
is consistent with data showing that purified KIF17-
Tail can bind MTs in vitro [43]. Interestingly, although 
nuclear accumulation of ERR1 was not inhibited by MT 
depolymerization, expression of the KIF17-T still inhibited 
ERR1 transcriptional activity in luciferase reporter assays 
under these conditions (Figure 3D). From these data, we 
conclude that the KIF17 Tail domain can inhibit ERR1 
function in the nuclear compartment, independent of MTs. 
A KIF17-Tail peptide containing an LXXLL NR 
box motif is necessary and sufficient to inhibit 
ERR1-mediated transcription
To more fully characterize how KIF17 interacts with 
ERR1 and to further explore the mechanism by which 
it affects ERR1 function, we analyzed the amino acid 
sequence of the KIF17 tail domain. We identified a nuclear 
receptor box (NR box) motif comprised of LXXLL 
residues near the N-terminal region of KIF17-T (Figure 
4A). The LXXLL motif is found in nuclear receptor co-
activators and mediates their binding to nuclear receptors 
[31-33]. To determine if this LXXLL motif is necessary 
for inhibition of ERR1 by KIF17-T, we generated an 
N-terminal truncation mutant in which 12 amino acids, 
inclusive of the NR box, were removed from KIF17-T 
(KIF17-TΔNR, underlined amino acids were deleted, Figure 
4A). We co-expressed GFP-KIF17-TΔNR and ERRE-Luc 
in ER-positive and ER-negative cells and measured 
luminescence 24h after transfection. Unlike wild-type 
KIF17-T, KIF17-TΔNR did not inhibit ERR1 transcriptional 
activity, and instead amplified transcription relative to 
controls (Figure 4C). Interestingly, we found that myc-
KIF17-TΔNR co-immunoprecipitated with GFP-ERR1 
(Figure 4B), albeit less efficiently, and that expression of 
KIF17-TΔNR attenuated ERR1 nuclear accumulation to the 
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Figure 3: KIF17-Tail attenuates nuclear accumulation of ERR1 in both ER-positive and ER-negative breast cancer 
cells. A. Upper panels: Localization of endogenous ERR1 (red) and KIF17 (green) in MCF7 (left panel) and MCF10a (right panel) cells. 
Lower panels: Localization of ERR1, KIF17 and MTs (cyan) in MCF-7 cells. ERR1 signal in this image was attenuated by modifying 
the LUT so that the MT array could be more easily visualized. The ROI indicated in this panel showing the entire cell is magnified in 
the right panel to highlight ERR1 and KIF17 along individual MTs. Graph and table show line-scan and quantification of ERR1 and 
KIF17 fluorescence intensities over a 10µm length of an individual MT. Solid circles on the image show overlapping fluorescence peaks 
on the line-scan. Dashed circles show other overlapping puncta on different MTs that are not represented in the line-scan. N = 63 MTs 
analyzed. B. Schematic describing the experimental protocol used for time-lapse imaging of GFP-ERR1 nuclear accumulation. Images 
show representative cells expressing GFP-ERR1 after cDNA injection in the first (t0) and last (t180) frames of a time-lapse in MCF-7 cells. 
After image acquisition, regions of interest were drawn defining individual cells (yellow outline) and nuclear boundaries (blue outline) at 
the first and last time points. GFP integrated fluorescence intensities were measured and the ratio of Nuclear/Total (N/T) GFP-ERR1 was 
calculated. C. MCF-7 cells injected with GFP-ERR1 and mCh-KIF17-T or control, mCh-EV cDNAs. Images show GFP-ERR1 in first and 
last frames of time-lapse recordings. Insets: mCh-EV control and mCh-KIF17-T in injected cells. Table: pooled data from 3 experiments 
reporting (i) % nuclear GFP-ERR1 at indicated times, (ii) the change in % nuclear fluorescence (∆N/T), and (iii) the % inhibition of 
nuclear accumulation by expression of KIF17-T. D. Luminescence measured in untreated and NZ-treated MCF7 and MDA-MB-231 cells 
expressing ERRE-Luc and GFP-KIF17-T or control GFP-EV. Graphs show normalized luminescence values pooled from ≥ 3 experiments 
performed in triplicate. Error bars = SEM. *** p < 0.05. Scale bars = 25μm unless otherwise noted.
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Figure 4: A 12 amino acid peptide in the KIF17-Tail is necessary and sufficient to inhibit ERR1 transcriptional activity. 
A. Sequence of the KIF17-Tail. The 12 amino acid NR box peptide containing the LXXLL motif is underlined. B. Co-immunoprecipitation 
of GFP-ERR1 with myc-EV control, myc-KIF17-T or myc-KIF17TΔNR expressed in HEK293 cells. Immunoprecipitates and total lysates 
were analyzed by immunoblot using anti-GFP and anti-myc IgG. C., D. Luciferase reporter assays showing transcriptional activity of 
endogenous ERR1 in MCF7 cells expressing ERRE-Luc and myc-EV, myc-KIF17-T, myc-KIF17ΔNR (panel C) or myc-KIF17NR (panel 
D). E. Luciferase reporter assays showing transcriptional activity of endogenous ERR1 in parental LM2 and LM2NR cells transfected with 
ERRE-Luc. F. Same as in panel E, but comparing cells transfected with control or ERR1 siRNAs. Graphs show normalized luminescence 
values pooled from ≥ 3 experiments performed in triplicate. Error = SEM. ***p < 0.05.
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same extent as KIF17-T (not shown). Thus these 12 amino 
acids are not required for binding of KIF17-T to ERR1, 
but are necessary to modify ERR1activity. Considered 
together, these data suggest additional sequences in the 
KIF17-Tail domain contribute to ERR1 binding, and 
that the effects of KIF17 on ERR1 function are mediated 
primarily through interaction of the KIF17 NR box motif 
with ERR1 in the nuclear compartment. 
To determine if this LXXLL-containing peptide 
in KIF17-Tail is sufficient to inhibit ERR1 function, we 
generated expression constructs encoding only these 12 
amino acids (KIF17-TNR, underlined amino acids, Figure 
4A). We co-expressed ERRE-Luc and GFP-KIF17-
TNR in ER-positive and ER-negative cells and measured 
luminescence 24h after transfection. KIF17-TNR inhibited 
ERR1-mediated transcription, like wild-type KIF17-T, as 
compared with cells co-expressing empty vector controls 
(Figure 4D). Expression of myc-tagged KIF17-TNR was 
equally effective in reducing luminescence, showing that 
the GFP moiety does not interfere with peptide activity 
(data not shown). 
We also generated a cell line stably expressing 
GFP-KIF17-TNR peptide at lower levels than in transiently 
transfected cells, which we use in tests of the physiological 
consequences of KIF17-mediated modulation of ERR1 
(see below). Stable transfectants were produced in the 
highly invasive MDA-MB-LM2 cell line [44] and are 
denoted LM2NR henceforth. Analysis of luciferase activity 
in parental LM2 and LM2NR cells 24hr after transfecting 
ERRE-Luc showed that luminescence was significantly 
lower in LM2NR as compared with control LM2 cells 
(Figure 4E). We measured a similar reduction in luciferase 
activity using LM2 cells stably expressing GFP-KIF17-T 
(not shown). Importantly, the reduction in ERRE-Luc 
activity measured in LM2NR cells was similar in LM2 
parental cells depleted of ERR1 by siRNA-mediated 
knock-down; ERR1 depletion in LM2NR cells did not result 
in further reduction of luciferase activity (Figure 4F). This 
finding suggests that the remaining transcriptional activity 
measured in these cultures is likely due to the activity of 
ERR3, which also binds the ERRE [10] and is consistent 
with our finding that the KIF17-Tail does not interact 
with ERR3. Together, these data show that a KIF17-Tail 
dodeca-peptide containing an NR box motif is necessary 
and sufficient to inhibit ERR1-mediated transcription. 
The KIF17 NR box motif attenuates ERR1 
transcriptional activity selectively and inhibits cell 
invasion through matrigel
To determine if expression KIF17-T or KIF17-TNR 
affects the transcription of known and potentially new 
ERR1 targets, we performed qPCR using RNA isolated 
from control LM2 cells stably expressing GFP-empty 
plasmid, LM2NR and LM2-KIF17-T cells. In our analysis 
of previously described ERR1 targets [6], we found that 
stable expression of GFP-KIF17-T or GFP-KIF17NR 
significantly reduced transcription of ERR1 and HIF1A, 
but not osteopontin, aromatase, PGC1A or TFF-1 (Figure 
5A). As expected in the case of HIF1A suppression, a 
preliminary differential RNAseq analysis of LM2NR and 
control LM2 cells (not shown) also revealed attenuated 
expression of ICAM-1 and angiopoietins, which are 
regulated by HIF1A [45]. Consistent with the lack of 
change in PGC1A, a key co-activator of genes involved 
in mitochondrial biogenesis and function, we observed 
no differences in mitochondrial mass or function in 
fluorescence-based assays (not shown), nor did we detect 
significant changes in mitochondrial genes by RNAseq in 
LM2 NR cells. Thus the KIF17-Tail domain and the KIF17 
NR box motif peptide inhibit transcription of a subset of 
known ERR1 targets. 
Stable expression of GFP-KIF17-T or GFP-KIF17NR 
in LM2 cells also significantly inhibited transcription 
of Claudin-4, 14-3-3ζ/δ, and presenilin (Figure 5A), 
potentially new ERR1 targets we identified as down-
regulated in LM2NR cells by RNAseq analysis (not shown). 
Whether these represent bona fide ERR1 transcriptional 
targets is not yet clear and will be determined directly by 
ChIPseq in follow-up studies. Claudin-4 and 14-3-3δ/ζ, 
are of particular interest in the breast cancer landscape. 
High expression of claudin-4 in primary tumors, and 
particularly in distant metastases, is a negative prognostic 
indicator in ER(-) and triple-negative breast cancer 
patients and is a powerful predictor of survival [46-50]. 
High expression of 14-3-3δ/ζ is a negative prognostic 
biomarker associated with tamoxifen resistance in ER+ 
patients [51-53]. Identifying potential ways to modulate 
their expression could reveal additional cancer treatment 
modalities. 
To determine the consequences of KIF17 mediated 
modulation of ERR1 transcriptional targets on cell 
behavior, we performed trans-well invasion and 2D 
migration assays with parental LM2 and LM2NR cells. For 
invasion assays, serum-starved cells were seeded in serum-
free medium on the upper surface of Matrigel-coated 
trans-well filters with 8µM pores. Complete medium 
containing 5% FBS was added to the lower chamber and 
cultures were incubated 10h before fixation and analysis 
of cells that had invaded the Matrigel and emerged on 
the bottom surface of the filter. Invasion of LM2NR cells 
was significantly impaired as compared with parental 
LM2 cells (Figure 5B). These results are consistent with 
reduced invasion observed with siRNA mediated knock-
down of ERR1 levels seen in multiple different cell types 
[54]. For analysis of migration in 2D, monolayer cells 
were scratch-wounded and cell migration/wound closure 
was monitored by time-lapse imaging over a 6h period. 
We measured no significant differences in cell migration 
rate and extent of wound closure between parental LM2 
and LM2NR cells (Figure 5C). This contrasts reports that 
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depletion of ERR1 with siRNA inhibits both cell invasion 
(3D) and migration (2D) [54] and likely reflects selective 
effects of expressing KIF17-TNR on the ability of LM2NR 
cells to degrade extracellular matrix. Thus inhibition of 
ERR1 activity with the KIF17 tail NR box peptide does 
not globally affect cellular processes associated with 
Figure 5: Stable expression of KIF17NR or KIF17-Tail in LM2 cells attenuates transcription of a subset of ERR1 
targets and inhibits invasion through materiel. A. qPCR analysis of known and possible new ERR1 targets in LM2, LM2NR and 
LM2-KIF17-Tail cells. Error = SEM. ***p < 0.0005, **p < 0.005, *p < 0.05. B. Trans-well Matrigel invasion of parental LM2 and LM2NR 
cells. Images show representative regions of invaded cells. Graph shows fold change in invasion compared to parental LM2 cells and are 
pooled from duplicate samples from ≥ 3 experiments. Error bars = SEM. ***p < 0.05. Scale bar = 25µm. C. Cell migration into a wound 
by LM2 and LM2NR cells. Solid lines show the cell front at the first time point. Dotted lines show the cell front in the final frame of the 
time-lapse (t = 6hrs). Scale bar = 50µm. Images are representative of cell migration in 6 random fields over time. Graph shows pooled data 
from ≥ 3 experiments. Error bars = SEM.
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downstream outputs of ERR1 transcription. This finding 
also highlights the potential of this peptide as a selective 
inhibitor of ERR1 regulated cell behaviors.
DISCUSSION
The data presented here document a previously 
unreported interaction between the kinesin KIF17 and 
the orphan nuclear receptor ERR1 and suggest KIF17 
plays a selective, regulatory role in modulating ERR1 
transcriptional activity and downstream cellular behaviors 
associated with expression of ERR1 target genes. Our 
data showing that ERR1 activity is elevated significantly 
in KIF17-/- cells, and that re-expression of the KIF17 
tail domain is sufficient to reduce ERR1 activity back to 
normal levels measured in wild-type KIF17+/+ cells further 
indicates that this kinesin has a physiologically relevant 
function in modulating ERR1-mediated transcription. 
Cumulatively, our data lead us to propose a model 
in which KIF17 can modulate ERR1 by two possible, 
non-exclusive mechanisms: by controlling the nuclear-
cytoplasmic distribution of ERR1 and by acting as a 
repressor of ERR1-mediated transcription in the nucleus 
(Figure 6). This idea is supported by data showing that 
(i) endogenous KIF17 (and expressed KIF17 or KIF17-
Tail) localizes to both the cytoplasmic and nuclear 
Figure 6: Proposed model of KIF17-mediated regulation of ERR1. Endogenous KIF17, expressed KIF17-FL, or KIF17-Tail in 
the cytoplasmic compartment could impact ERR1 function by sequestering ERR1 on MTs in the cytoplasm. In the nuclear compartment, 
endogenous KIF17, expressed KIF17-FL, KIF17-Tail or KIF17-TNR could impact ERR1 function by competing with transcriptional 
coactivators for binding to ERR1. KIF17∆NR lacking the NR box motif binds ERR1 but does not inhibit its activity; thus the NR box is 
necessary for KIF17-mediated modulation of ERR1 nuclear function.
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compartments and (ii) over-expressed KIF17-Tail 
attenuates nuclear accumulation of newly synthesized 
ERR1 and inhibits ERR1 transcriptional activity in 
cells with or without an intact MT network. Several 
reports show that kinesins, including the testis specific 
isoform of KIF17 (KIF17b), can bind and sequester 
transcriptional regulators in the cytoplasm as a way to 
modify transcriptional signaling [27, 30, 55, 56]. An intact 
MT network is needed for the sequestration function of 
these kinesins, but MT-stimulated, kinesin ATPase activity 
is not, demonstrating that these motors participate in 
transcriptional regulation by acting as cytoplasmic tethers 
rather than active transporters. Protein tethering on MTs 
represents a potentially effective way to insure proper 
temporal and spatial control of regulated transcription 
pathways as MTs are the major cellular highways for long-
distance transport and can facilitate productive encounters 
between signaling pathway molecules at discrete locations 
in cells. MT motors can also impact transcription by 
acting in their capacity as transporters, and this has been 
well documented in the case of cytoplasmic dynein, 
another class of MT-associated motor, which delivers 
its transcription factor cargoes to the nucleus for import 
[57-60]. Because we find that inhibition of ERR1 nuclear 
accumulation by KIF17-Tail requires intact MTs, we 
envision KIF17 most likely impacts ERR1 localization by 
acting as a MT tether. In addition, the KIF17 tail alone 
is not competent to move on MTs, but it can bind MTs 
in vitro independent of its canonical N-terminal, MT-
binding and motor domain [43]. As such, its ability to 
inhibit ERR1 nuclear accumulation in our assays was not 
unexpected and further supports the idea that KIF17 can 
act in part as a cytoplasmic tethering factor for ERR1. 
KIF17 could also affect ERR1 transcriptional 
activity by repressing its function within the nuclear 
compartment. This idea is bolstered by our finding that, 
in addition to an NLS, the KIF17 tail domain contains a 
conserved LXXLL NR box motif found in transcriptional 
co-activators. Transcriptional co-factors regulate binding 
of ERR1 to ERREs on target gene DNA [61, 62]. For 
canonical NRs, ligand binding induces a conformational 
change that accommodates the NR box motifs co-
activators [33]. Distinctive NR box-flanking residues 
classify co-activators into three general categories and 
mediate recognition of additional NR structural features 
that impact their binding to specific NRs in response to 
diverse signaling pathways [33, 61]. Unlike canonical 
NRs, ERR1 and other orphans interact with co-regulators 
in a ligand-independent manner and thus can affect 
transcription constitutively [9, 11]. However, ERR1-
coactivator interactions are regulated by competitive 
binding at co-activator sites, and by signal-mediated 
post-translational modifications that affect co-activator 
affinity for ERR1 [12, 13, 17, 22, 63-65]. Here, we 
show that a 12 amino acid KIF17 NR box peptide is 
necessary and sufficient to inhibit ERR1 activity. It is also 
sufficient to inhibit invasive behavior of breast cancer 
cells. This peptide bears signatures of NR co-activators 
with hydrophobic amino acids at the -1 position relative 
to LXXLL [31, 33]. Interestingly, deletion of the KIF17 
NR box peptide does not affect binding of the KIF17-
Tail to ERR1 and expression of KIF17-T∆NR results in 
increased ERR1 activity. This is an unexpected result 
and we speculate that removal of the KIF17 NR peptide 
allows ERR1 to access additional factors which enhance 
its function. Together, these data suggest KIF17 inhibits 
nuclear functions of ERR1 by competing with co-
activators for ERR1 binding. 
ER-negative breast tumors are resistant to 
chemotherapeutics targeting ER and estrogen production, 
and this resistance is partially attributable to ligand-
independent activities of ERR1, loss of ER-mediated 
competition for regulatory cofactors, and the ability of 
ERR1 to stimulate ER target genes independently of 
ER, particularly in the breast cancer landscape [6]. The 
association of high ERR1 levels with poor prognoses, 
particularly in ER-negative/ErbB2(+) and triple-negative 
breast cancer, has heightened interest in targeting ERR1 
and its modulators pharmacologically in breast and 
other steroidogenic cancers [66, 67]. Inverse agonists 
that interact with ERR1 have been identified and, like 
ERR1 silencing, they retard orthotopic tumor growth 
and inhibit migration of breast cancer cells in culture 
[16, 23, 24]. Mechanistically, these compounds interact 
with ERR1 in its predicted, but physiologically unused 
ligand binding domain, inducing a conformational change 
that inhibits co-activator binding, and leads ultimately 
to ERR1 degradation by the proteasome [20-22, 68]. To 
our knowledge however, none of these inhibitors are in 
clinical trial; most likely this is because they are predicted 
to induce systemic toxicity considering ERR1’s control 
of genes in multiple, essential pathways. Attractive 
alternative therapeutics would modify co-factor binding 
selectively, and could be tailored to affect only the subset 
of ERR1 targets altered in the disease state. The selective 
effects of expressing the KIF17-Tail or KIF17 NR-box 
peptide on expression of known, and possibly new, ERR1 
targets suggest a KIF17-based treatment modality could be 
exploited in such a manner.
The data presented here document a new mechanism 
to regulate ERR1 activity in breast cancer cells and reveal 
a new and direct mode by which kinesins can impact 
transcription. Our findings support a hypothesis that 
KIF17-ERR1 interactions could be exploited to selectively 
inhibit subsets of ERR1 targets and down-stream cellular 
processes. Notably, the ability the LXXLL-containing 
KIF17 NR box peptide to inhibit ERR1 transcriptional 
activity suggests it could be used, with or without 
additional modification, as a tool to attenuate ERR1 
function in breast cancer. In the future, it will be important 
to determine the effects of altering LXXLL flanking 
sequences on transcriptional outputs of ERR1 action. It 
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will also be interesting to determine if additional kinesins 
are engaged similarly to regulate ERR1 and other NRs.
MATERIALS AND METHODS
Cell culture, transfection, and microinjection
MCF7, MDA-MB-231, MDA-MB-LM2 (LM2) and 
HEK293T cells (ATCC) were cultured in DMEM (4.5 g/
liter glucose) with 10% FBS and 20 mM Hepes, pH 7.2. 
MCF10a cells were cultured in DMEM:F12 50/50 with 
5% FBS, 0.5mg/mL hydrocortisone, 100ng/mL cholera 
toxin and 20ng/mL EGF. MCF-7, MCF-10A, MDA-
MB-231 and LM2 cells were transfected with 10µg DNA 
using the AmaxaTM nucleofector (Lonza) as recommended. 
HEK293T cells were transfected using JetPrimeTM 
(Polyplus Transfection, Illkirch, France) as recommended. 
Microinjection was performed as described [40]. Briefly, 
5-20 µg/ml cDNAs in HKCl (10 mM Hepes, 140 mM 
KCl, pH 7.4) were pressure injected into cell nuclei using 
a micromanipulator (MMO-202ND; Narishige). Cells 
were incubated at 37°C for 90min to allow for expression 
of cDNAs.
Generation of stable cell lines
LM2NR cells were generated by transfecting LM2 
cells with GFP-KIF17-TNR followed by sorting using the 
FACSAria II cell sorter (BD Biosciences). Transfected cell 
populations were maintained in media containing 2μg/mL 
of G418 during the first two rounds of cell sorting, after 
which G418 was omitted. Genome-edited, KIF17 knock-
out T84 cells were generated by transfecting plasmids 
designed for genome-wide, Cas9-mediated knock-out 
of human KIF17 (KN209079, OriGene). Cells were 
passaged once and subjected to puromycin selection (6μg/
mL) for one week. Individual puromycin-resistant clones 
were selected using cloning rings and expanded. KIF17 
knock-out was determined in each clone by Western blot. 
Experiments were performed in two of the KIF17-/- clonal 
cell lines.
Expression constructs
KIF17-TΔNR, KIF17-TNR peptide, ERR1 and ERR3 
were amplified by PCR from human Caco2 cells and 
cloned into GatewayTM expression vectors (Invitrogen). 
Primers: KIF17-TΔNR: forward; 5’-GGG GAC AAG TTT 
GTA CAA AAA AGC AGG CTC CGA GCA GGT GCA 
GCC CCT GAT TC and reverse; GGG GAC CAC TTT 
GTA CAA GAA AGC TGG GTC TCA CAG AGG CTC 
ACT GCC AAA GTT-3’. KIF17-TNR peptide: forward; 
5’-GGG GAC AAG TTT GTA CAA AAA AGC AGG 
CTC CCA GGA GCG TGA CTC CAT GC and reverse; 
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC 
CAG GAG CTG CTG CAA GAG C-3’. ERR3: forward; 
5’- GGG GAC AAG TTT GTA CAA AAA GCA GGC 
TCC ATG TCA AAC AAA GAT CGA C and reverse; 
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC 
GAC CTT GGC CTC CAA CAT T-3’. The KIF17-Tail and 
KIF1A-Tail constructs were described previously [40], 
[69]. ERR1: forward; 5’ - GTA CAA AAA AGC AGG 
CTT CTC CAG GGA GGT GGT GGG C and reverse; 
GTA CAA GAA AGC TGG GTC TCA GTC CAT CAT 
GGC CTC GAG. ERRE-Luc reporter was provided by JM 
Vanacker (University of Lyon, France). 3X-ERE-Luc was 
purchased from Addgene (Plasmid 11354). All constructs 
were verified by sequencing prior to use in experiments. 
Knock-down of ERRA by siRNA
5µg siRNA was transfected into cells using AMAXA 
electroporation and ERRA levels were monitored by 
western blot. Cells were harvested 3 days after transfection 
and used in luciferase reporter assays. ERRA siRNAs used 
targeted sense strand 5’ GAG CAU CCC AGG CUU CUC 
AUT T and antisense strand AUG AGA AGC CUG GGA 
UGC UCT T 3’ and have been described previously [70, 
71]. Scrambled siRNA was used as a control.
Yeast 2-hybrid
A yeast-2-hybrid library from normal colon 
epithelial cells (25µg) was screened using the C-terminal 
tail domain of KIF17 as bait as described previously [72]. 
7.2 x 106 clones were analyzed with 432 positives detected. 
Clones detected in iterative rounds of screening were 
used as PCR templates to prepare tagged, mammalian 
expression constructs for further analysis. We confirmed 
that clones encoding a.a. 254-423 of ERR1 interacted 
with  KIF17 tail domain by co-immunoprecipitation in 
transfected HEK-293 cells. 
Immunoblotting and co-immunoprecipitation
Immunoprecipitation of expressed proteins was 
performed using lysates from HEK293 cells transfected 
with indicated constructs. One day after transfection, 
cells were lysed in lysis buffer (50mM HEPES, pH 7.4 
containing, 150mM NaCl, 1.5mM MgCl2, 0.5mM CaCl2, 
10% (v/v) glycerol, 1% (v/v) Triton-X100, 1mM PMSF, 
and 0.5mg/ml each of leupeptin, bestatin, pepstatin) 
with rocking for 30 minutes. Lysates were cleared using 
Protein-G sepharose beads (GE Healthcare) and incubated 
overnight with 6-8μg rabbit anti-GFP antibody (Novus 
Biologicals, NB 600-303) or mouse anti-myc antibody 
(Sigma M4439). Immunoprecipitation of endogenous 
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protein was performed using MCF-7 cells. Cells were 
grown to confluence and lysed for 30 minutes. Lysates 
were cleared using Protein-G sepharose and incubated 
overnight with 10μg mouse anti-ERR1 antibody (Abcam 
ab418618). Other primary antibodies include mouse anti-
GFP (Roche, 1814460), rabbit anti-myc (Cell Signaling, 
2276S), goat anti-ERRα (Santa Cruz Biotechnology, sc-
32971) and goat anti-KIF17 IgG (M20, Santa Cruz). 
Luciferase reporter assays
24h after transfection cells were washed with PBS 
and lysed using Glo-lysis buffer (Promega) for 5min. 
Lysates were collected and mixed 1:1 with BrightGlo 
Luciferase assay reagent (Promega) and luminescence 
measured using a Luminometer (Synergy H1, BioTek). 
For MT depolymerization experiments, cells were treated 
with 33µM nocodazole for 270 minutes before addition of 
Glo-lysis buffer. Results were corrected for background 
luminescence and plotted using GraphPad Prism 5. 
Statistical significance, p < 0.05, was determined using 
Bonferroni analysis.
Immunofluorescence
Cells were fixed in −20°C methanol for 1-2 min. 
Microtubules were detected using YL1/2 rat-anti-
tyrosinated tubulin (J. Kilmartin). KIF17 was detected 
with rabbit anti-KIF17 IgG (Sigma, K3638). ERR1 was 
detected with goat anti-ERR1 IgG (Santa Cruz, sc-32971). 
Fluorescently conjugated secondary antibodies were 
from Jackson ImmunoResearch. Images were acquired 
with a Neo sCMOS camera (6.45µm pixels, 560MHz, 
Andor Technology) on a Nikon TiE inverted microscope 
(Nikon Inc., Mellville, NY) using 40X (NA 1.0) or 60X 
(NA 1.4) plan apochromat oil immersion objectives. 14-
16bit images were scaled linearly to highlight features of 
interest and converted to 8-bit copies for figure assembly. 
Devices were controlled by Elements software (Nikon 
Instruments). Line-scan analysis: The number of ERR1 
and KIF17 puncta on MTs, and their colocalization shown 
in Figure 4A, was determined by line-scan analysis 
of fluorescence intensities along 10µm of individual 
MTs. Overlapping fluorescence peaks were scored as 
colocalized puncta. 
Time-lapse imaging and analysis
For time-lapse imaging, cells were transferred to 
recording medium (Hanks balanced salt solution with 20 
mM Hepes, 1% FBS, 4.5 g/liter glucose, essential and 
nonessential amino acids) and incubated at 37°C in a 
thermal-controlled chamber (Harvard Apparatus) on the 
microscope. Time-lapse images were acquired at 10min 
intervals for 3h using a 20x (NA 0.75) plan apochromat 
objective or a 20x (NA 0.5) plan fluor, phase contrast 
objective and images were collected with a Neo sCMOS 
camera as described above. 
Nuclear translocation of GFP-ERR1
Following image collection, background 
fluorescence was subtracted from 16-bit images. Regions 
of interest (ROIs) were drawn after morphometric 
thresholding around individual cells and their 
corresponding nuclei. Integrated florescence intensities 
were calculated for nuclear ROI (N) and total ROI (T) and 
expressed as a ratio, N/T, per individual cell over time. 
Average N/T per cell at the start and end time points were 
plotted using Graphpad Prism 5. For MT depolymerization 
experiments, cells were treated with 33µM nocodazole 
(NZ) immediately following cDNA injection and cells 
were maintained in NZ for the duration of the experiment.
Cell migration
Cells were grown on cover slips until a monolayer 
was formed and wounded using a sterile pipette. Time-
lapse recordings were started 3h after wounding, with 
images acquired at 10m intervals for a duration of 6 hours. 
Images were thresholded to define the wound area, which 
was quantified using Nikon Elements software. Results 
were plotted Graphpad Prism 5. 
Trans-well invasion assay
Matrigel™ Invasion Chambers (Corning, part 
#354480) were hydrated overnight in serum-free DMEM. 
Cells were trypsinized, resuspended in serum-free DMEM 
and counted. 2x105 cells were added to the upper chamber 
in serum-free DMEM. DMEM with 5% FBS, or serum-
free DMEM as a control, was added to the lower chamber. 
Duplicate samples for each condition were analyzed in 3 
independent experiments. Cells were incubated at 37°C 
for 10hrs. Following incubation, media was aspirated 
carefully, cells were fixed in 4% paraformaldehyde for 
5 minutes and stained using 0.05% crystal violet for 5 
minutes. Membranes were washed, excess Matrigel and 
cells remaining in the upper chamber were removed using 
low-lint G-tip swabs. Filters were dried, excised from the 
inserts and mounted onto slides for imaging. 6 x 2.3mm2 
fields per membrane were imaged using a 10x (0.3 NA) 
plan fluor objective. Cells stained with crystal violet were 
outlined by morphometric thresholding and counted using 
Nikon Elements software. Unusually large cell clusters/
clumps were excluded from the analysis. Results were 
plotted using Graphpad Prism 5.
qRT-PCR
qRT-PCR was performed on a Taqman 7900HT 
using standard methods. Total RNA and cDNA was 
obtained from stable cell lines using Qiagen RNAeasy 
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RNA extraction kit and cDNA generated using standard 
methods. GAPDH was used as a control. All primers 
were obtained from Integrated DNA Technologies. TET/
ZEN/IBFQ was used as the dye-quencher on probes 
for GAPDH. 6-FAM/ZEN/IBFQ was used as the dye-
quencher for all other primers. The following primers were 
used. ERR1: Forward 5’ CTA TGG TGT GGC ATC CTG 
TG 3’ and reverse TCT CCG CTT GGT GAT CTC A 3’ 
and , Osteopontin: Forward 5’ CCC CAC AGT AGA CAC 
ATA TGA TG and reverse TTC AAC TCC TCG CTT TCC 
AT 3’, Aromatase: Forward 5’ AGA GGA AAC ACT CAT 
TAT CAG CA and reverse GCC TTT CTC ATG CAT ACC 
GAT 3’, Presenilin: Forward 5’ TCC CTT GAC TGG CTA 
CCC and reverse CCA GCA CAC TGT AGA AGA TGA 
3’, 14-3-3 ζ/δ:Forward 5’ GCA TGA AGT CTG TAA CTG 
AGC A and reverse GCA CCT TCC GTC TTT TGT TC 
3’, Claudin-4: Forward 5’ CCA TAT AAC TGC TCA ACC 
TGT CC and reverse AGA TAA AGC CAG TCC TGA 
TGC 3’, GAPDH: Forward 5’ ACA TCG CTC AGA CAC 
CAT G and reverse TGT AGT TGA GGT CAA TGA AGG 
G 3’, HIF2: Forward 5’ AGC CTA TGA ATT CTA CCA 
TGC G and reverse CTT TGC GAG CAT CCG GTA 3’ , 
TFF1: Forward 5’ CCA TGG AGA ACA AGG TGA TCT 
and reverse TGA CAC CAG GAA AAC CAC AA 3’ ’, 
HIF1A: Forward 5’ CTC TGA TCA TCT GAC CAA AAC 
TCA and reverse CAA CCC AGA CAT ATC CAC CTC 
3’ , PGC1A (exon 8-9): Forward 5’ GTC CTT TTC TCG 
ACA CAG GT and reverse GTC TGT AGT GGC TTG 
ACT CAT AG 3’ , PGC1A (exon 1-2): Forward 5’ GAG 
TCT GTA TGG AGT GAC ATC G and reverse TGT CTG 
TAT CCA AGT CGT TCA C 3’ .
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